- PROFESSOR AND SYSTEM CHAIR Pathology
- PROFESSOR Genetics and Genomic Sciences
- PROFESSOR Oncological Sciences
Ph.D., Cornell University Medical College
Carlos Cordon-Cardo, MD, PhD is recognized internationally for his groundbreaking research in experimental pathology and molecular oncology, holds the appointment of Chair for the Department of Pathology at The Mount Sinai Medical Center.
Dr. Cordon-Cardo is a leader in the mechanisms of tumor suppression. His research has focused on the analyses of multidrug resistance and alteration of tumor suppression genes in human cancer. He developed and implemented an oncologic molecular pathology discipline and helped create the “systems pathology” platform. This approach uses systems biology to form mathematical models of the interaction and behavior of cancer cells with the goal of determining tumor pathogenesis and
Dr. Cordon-Cardo’s contributions to cancer research have had important implications for tumor suppression, particularly in bladder and prostate cancers, and soft tissue sarcomas. Currently, his research is aimed at understanding the cooperative effects of mutations of cell-cycle regulation, and genes that prevent cell death cancer. Additionally, he is developing and characterizing animal models for loss of function of specific pathways by targeted gene disruption using bladder cancer and sarcomas. Recent studies from his laboratory have linked adult stem cells and cancer, revealing that certain tumors originate from distinct differentiation stages in stem-cell fate and development.
A frequently cited author, Dr. Cordon-Cardo has received National Cancer Institute funding for his research. He has developed numerous patents, is a dedicated mentor, and he holds prominent posts in several national and international professional organizations.
Dr. Cordon-Cardo has outlined a broad vision that redefines the discipline of Pathology, placing it at the core of patient management and individualized medicine. He is aggressively recruiting senior and junior faculty, identifying and developing subspecialty areas, such as molecular and systems pathology programs, and expanding biorepositories and databases to further enhance translational research, converting his vision into a reality.
Prior to joining Mount Sinai, Dr. Cordon-Cardo served as Vice-Chair of Pathology, Professor of Pathology, and Urology, and Associate Director for Infrastructure at the Herbert Irving Comprehensive Cancer Center at Columbia University College of Physicians and Surgeons. He also created the Division of Molecular Pathology at Memorial Sloan-Kettering Cancer Center and served as its first director.
Dr. Cordon-Cardo obtained his MD from the Autonomous University of Barcelona, Spain, in 1980, and his PhD in Cell Biology and Genetics from Cornell University Medical College in 1985.
In The News: Dr. Carlos Cordon-Cardo discusses new techniques in the fight against prostate cancer in The Daily News feature The Daily Check Up.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Cordon-Cardo during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Exosome Diagnostics, Inc.; Laboratorio Althia (Europath Biosciencies S.L.)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
One Gustave L. Levy Place
New York, NY 10029